Vera Therapeutics Reports Q1 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: seekingalpha
- Financial Performance: Vera Therapeutics reported a Q1 GAAP EPS of -$1.69, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Flow Situation: For the quarter ending March 31, 2026, net cash used in operating activities was $106.5 million, a substantial increase from $54.4 million in the same quarter of 2025, suggesting pressure on the company's financial management that may affect future investment capabilities.
- Market Reaction: Analysts downgraded the rating to Hold based on the reassessment of Atacicept's potential in treating IgAN, reflecting a cautious market sentiment regarding the company's product prospects, which may lead to decreased investor confidence in future growth.
- Industry Conference: Vera Therapeutics presented at the TD Cowen 46th Annual Health Care Conference, actively seeking to communicate with investors despite financial challenges, showcasing its ongoing efforts in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.340
Low
33.00
Averages
74.08
High
100.00
Current: 34.340
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhenman Exits Entire Stake in Vera Therapeutics
- Complete Exit: Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics during Q1 2026 for approximately $18.1 million, indicating a significant reduction in confidence in the company.
- Asset Value Decline: Prior to the sale, the value of Vera Therapeutics' position decreased by $21.27 million at quarter-end, reflecting the dual impact of market price fluctuations and share sales, highlighting the pressures faced by the company.
- Strong Stock Performance: As of May 13, 2026, Vera Therapeutics shares traded at $39.15, marking an 81.4% increase over the past year, significantly outperforming the S&P 500 by 55 percentage points, showcasing its robust performance in the biotech sector.
- Investment Risk Advisory: Despite a 378% increase in stock price over the past three years, Vera Therapeutics remains a biotech stock subject to volatility, particularly due to clinical data releases and drug approval processes, necessitating careful risk assessment by investors.
See More
Rhenman & Partners Exits Entire Stake in Vera Therapeutics
- Complete Exit: Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics during Q1 2026 for an estimated $18.10 million, indicating a significant reduction in confidence in the stock.
- Impact on AUM: The sale resulted in a decline of approximately $21.27 million in the position's value quarter over quarter, reflecting the dual impact of market price movements and share sales, leading to a zero percent allocation in the fund's 13F assets.
- Stock Performance Review: While Vera Therapeutics' stock has surged 81.4% over the past year and 378% over the last three years, it still carries volatility risks associated with clinical data releases and drug approval processes, necessitating careful investor consideration.
- Market Competition Analysis: Despite Vera Therapeutics' potential in the immunology therapeutics market, it was not included in The Motley Fool's current list of the top ten stocks to buy, suggesting a cautious market outlook on its future performance.
See More
Vera Therapeutics Reports Q1 Financial Results
- Financial Performance: Vera Therapeutics reported a Q1 GAAP EPS of -$1.69, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Flow Situation: For the quarter ending March 31, 2026, net cash used in operating activities was $106.5 million, a substantial increase from $54.4 million in the same quarter of 2025, suggesting pressure on the company's financial management that may affect future investment capabilities.
- Market Reaction: Analysts downgraded the rating to Hold based on the reassessment of Atacicept's potential in treating IgAN, reflecting a cautious market sentiment regarding the company's product prospects, which may lead to decreased investor confidence in future growth.
- Industry Conference: Vera Therapeutics presented at the TD Cowen 46th Annual Health Care Conference, actively seeking to communicate with investors despite financial challenges, showcasing its ongoing efforts in the healthcare sector.
See More
Vera Therapeutics to Present at Bank of America Health Care Conference
- Conference Participation: Vera Therapeutics' management team will present at the Bank of America Securities Health Care Conference on May 13, 2026, at 4:20 PM in Las Vegas, aiming to enhance the company's visibility and credibility among investors through one-on-one meetings.
- Lead Product Candidate: The company's lead product candidate, atacicept, is a self-administered weekly subcutaneous injection designed to treat serious immunological diseases by blocking BAFF and APRIL, which is expected to change the standard of care for conditions like IgA nephropathy and lupus nephritis.
- Research and Development Potential: Vera is also evaluating the clinical significance of atacicept in additional autoimmune diseases, showcasing its potential applications across a wide range of B-cell-mediated diseases, thereby enhancing its competitive position in the market.
- Exclusive Licensing Agreement: The company holds an exclusive license agreement with Stanford University for the development of the next-generation fusion protein VT-109, which is anticipated to offer broad therapeutic potential for B-cell-related diseases, further solidifying its research foundation.
See More
Vera Therapeutics Grants Stock Awards to New Employees
- Stock Option Grant: On April 8, 2026, Vera Therapeutics granted 258,200 non-qualified stock options to 89 new employees at an exercise price of $40.33 per share, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Restricted Stock Units: The company also awarded 131,925 restricted stock units (RSUs) that will vest over four years, with the first vesting on May 20, 2026, reflecting the company's commitment to long-term contributions from new employees and helping to boost employee loyalty.
- Compliance with Incentive Plan: The awards comply with Nasdaq Listing Rule 5635(c)(4), demonstrating Vera Therapeutics' adherence to regulations and transparency in attracting new talent, which enhances investor confidence in corporate governance.
- R&D Strategic Context: Vera Therapeutics focuses on developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, and the addition of new employees is expected to accelerate the R&D process.
See More
Vera Therapeutics Grants Stock Awards to New Chief Legal Officer
- Stock Option Grant: On March 23, 2026, Vera Therapeutics granted 56,850 non-qualified stock options to new Chief Legal Officer Jane Wright-Mitchell, with an exercise price of $40.73 per share, reflecting the closing price that day, aimed at attracting and retaining key talent.
- Restricted Stock Units: The award also includes 42,403 restricted stock units (RSUs) vesting over four years, demonstrating the company's commitment to the new employee and her significance in future business development.
- Vesting Arrangement: Both the stock options and RSUs are contingent on the new employee's continued service, ensuring long-term contributions to the company, reflecting Vera Therapeutics' emphasis on talent stability.
- Strategic Development Focus: Vera Therapeutics is dedicated to developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, showcasing the company's strategic foresight in the biotechnology sector.
See More
Rhenman Exits Entire Stake in Vera Therapeutics
- Complete Exit: Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics during Q1 2026 for approximately $18.1 million, indicating a significant reduction in confidence in the company.
- Asset Value Decline: Prior to the sale, the value of Vera Therapeutics' position decreased by $21.27 million at quarter-end, reflecting the dual impact of market price fluctuations and share sales, highlighting the pressures faced by the company.
- Strong Stock Performance: As of May 13, 2026, Vera Therapeutics shares traded at $39.15, marking an 81.4% increase over the past year, significantly outperforming the S&P 500 by 55 percentage points, showcasing its robust performance in the biotech sector.
- Investment Risk Advisory: Despite a 378% increase in stock price over the past three years, Vera Therapeutics remains a biotech stock subject to volatility, particularly due to clinical data releases and drug approval processes, necessitating careful risk assessment by investors.
See More
Rhenman & Partners Exits Entire Stake in Vera Therapeutics
- Complete Exit: Rhenman & Partners Asset Management AB sold its entire 420,000-share stake in Vera Therapeutics during Q1 2026 for an estimated $18.10 million, indicating a significant reduction in confidence in the stock.
- Impact on AUM: The sale resulted in a decline of approximately $21.27 million in the position's value quarter over quarter, reflecting the dual impact of market price movements and share sales, leading to a zero percent allocation in the fund's 13F assets.
- Stock Performance Review: While Vera Therapeutics' stock has surged 81.4% over the past year and 378% over the last three years, it still carries volatility risks associated with clinical data releases and drug approval processes, necessitating careful investor consideration.
- Market Competition Analysis: Despite Vera Therapeutics' potential in the immunology therapeutics market, it was not included in The Motley Fool's current list of the top ten stocks to buy, suggesting a cautious market outlook on its future performance.
See More
Vera Therapeutics Reports Q1 Financial Results
- Financial Performance: Vera Therapeutics reported a Q1 GAAP EPS of -$1.69, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Flow Situation: For the quarter ending March 31, 2026, net cash used in operating activities was $106.5 million, a substantial increase from $54.4 million in the same quarter of 2025, suggesting pressure on the company's financial management that may affect future investment capabilities.
- Market Reaction: Analysts downgraded the rating to Hold based on the reassessment of Atacicept's potential in treating IgAN, reflecting a cautious market sentiment regarding the company's product prospects, which may lead to decreased investor confidence in future growth.
- Industry Conference: Vera Therapeutics presented at the TD Cowen 46th Annual Health Care Conference, actively seeking to communicate with investors despite financial challenges, showcasing its ongoing efforts in the healthcare sector.
See More
Vera Therapeutics to Present at Bank of America Health Care Conference
- Conference Participation: Vera Therapeutics' management team will present at the Bank of America Securities Health Care Conference on May 13, 2026, at 4:20 PM in Las Vegas, aiming to enhance the company's visibility and credibility among investors through one-on-one meetings.
- Lead Product Candidate: The company's lead product candidate, atacicept, is a self-administered weekly subcutaneous injection designed to treat serious immunological diseases by blocking BAFF and APRIL, which is expected to change the standard of care for conditions like IgA nephropathy and lupus nephritis.
- Research and Development Potential: Vera is also evaluating the clinical significance of atacicept in additional autoimmune diseases, showcasing its potential applications across a wide range of B-cell-mediated diseases, thereby enhancing its competitive position in the market.
- Exclusive Licensing Agreement: The company holds an exclusive license agreement with Stanford University for the development of the next-generation fusion protein VT-109, which is anticipated to offer broad therapeutic potential for B-cell-related diseases, further solidifying its research foundation.
See More
Vera Therapeutics Grants Stock Awards to New Employees
- Stock Option Grant: On April 8, 2026, Vera Therapeutics granted 258,200 non-qualified stock options to 89 new employees at an exercise price of $40.33 per share, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Restricted Stock Units: The company also awarded 131,925 restricted stock units (RSUs) that will vest over four years, with the first vesting on May 20, 2026, reflecting the company's commitment to long-term contributions from new employees and helping to boost employee loyalty.
- Compliance with Incentive Plan: The awards comply with Nasdaq Listing Rule 5635(c)(4), demonstrating Vera Therapeutics' adherence to regulations and transparency in attracting new talent, which enhances investor confidence in corporate governance.
- R&D Strategic Context: Vera Therapeutics focuses on developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, and the addition of new employees is expected to accelerate the R&D process.
See More
Vera Therapeutics Grants Stock Awards to New Chief Legal Officer
- Stock Option Grant: On March 23, 2026, Vera Therapeutics granted 56,850 non-qualified stock options to new Chief Legal Officer Jane Wright-Mitchell, with an exercise price of $40.73 per share, reflecting the closing price that day, aimed at attracting and retaining key talent.
- Restricted Stock Units: The award also includes 42,403 restricted stock units (RSUs) vesting over four years, demonstrating the company's commitment to the new employee and her significance in future business development.
- Vesting Arrangement: Both the stock options and RSUs are contingent on the new employee's continued service, ensuring long-term contributions to the company, reflecting Vera Therapeutics' emphasis on talent stability.
- Strategic Development Focus: Vera Therapeutics is dedicated to developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, showcasing the company's strategic foresight in the biotechnology sector.
See More
